Thread by @BigBiteNow

(1/5)

#GDR RNS dated 22nd May ;

"genedrive's PCR bead format eliminates the need for the time consuming and error-prone reagent preparation required in all other open-platform test kits."

Key phrase : "all other" so competitive advantage.

(2/5)

"The proprietary format streamlines laboratory workflow, allowing more tests to be performed in a day."

More tests means lower customer costs, means competitive advantage, means more sales.

"The Genedrive® 96 SARS-CoV-2 kit is stable at ambient temperatures"

(3/5)
"which eliminates the need for cold storage, making the test very practical for global export markets."

"CE marking was achieved with performance studies and validations that. . . support regulatory applications in other jurisdictions, such as EUA with the USA FDA and"

(4/5)

"Emergency Use Assessment and Listing with the WHO."

"The temperature stable nature of the Genedrive® 96 SARS-CoV-2 kit means we have the potential to easily access these global markets, which are in urgent need of testing efficiency and volume."

(5/5)
Urgent need of testing efficiency and volume means sales and potentially lots of them.

GDR making it very clear where they see this product heading and for me the quality of the offering is being under appreciated.

There's a certain level of inevitability to what is now starting to happen at #GDR